The impact of development milestone timing on market exclusivityPosted: August 2, 2011
Nature Reviews – Drug Development has an interesting article in their July edition by Michael Dunn of Ferring Pharmaceuticals out of San Diego (no subscription required!). Michael did some research on the timing of various R&D events and their impact on the total duration of marketing exclusivity for a given drug.
It has some great background on how market exclusivity differs in the US and Europe and how events such as the filing of the first patent and the initiation of clinical trials impact the overall length of market exclusivity. I learned a few things from the article, so I thought I would pass it along.